EBM Technologies Incorporated (8409) Fair Value & Analysis
Healthcare · TW · Market cap 608M TWD
Fair value as of: Jul 22, 2026
From 13 valuation models · updated 19 days ago
Share price −5.2% over the past month.
A solid business, but screening 73% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (6.09 TWD). The favourable scenario is already priced in.
- Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 15.40 TWD – 34.95 TWD · fair‑value band 3.66 TWD – 6.09 TWD · the 18.10 TWD price screens above the 4.87 TWD fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
EBM Technologies Incorporated (8409) currently trades at 18.10 TWD, while our model-based Fair Value estimate is 4.87 TWD, implying the stock looks roughly 73.1% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, EBM Technologies Incorporated generated revenue of 281M TWD at a net margin of 11.1%. Revenue grew 121.8% year over year. It earns a return on equity of 10.3%. The stock trades on a trailing P/E of 79.6. Fundamentals as of Jul 22, 2026
Our scenario range runs from 3.66 TWD (bear case) to 6.09 TWD (bull case); at 18.10 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -73%, 8409 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: DCF Models (10.21 TWD) versus Earnings-Based (2.03 TWD). Highest evidence: ROIC Compounder (72).
Notify me when 8409 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
EBM Technologies Incorporated engages in the development and marketing of software and integrity solutions to the health sector in Taiwan and internationally.
Full company description
EBM Technologies Incorporated engages in the development and marketing of software and integrity solutions to the health sector in Taiwan and internationally. The company offers Enterprise PACS (picture archiving and communication systems) solutions, including SoliPACS that unites various products of the radiology, mammography, and dental fields; SoliPACS Gateway, a DICOM gateway; SoliPACS Server, an interface between HIS and RIS patient data and PACS; SoliPACS Web Viewer, which enables radiologists and physicians to view, compare, utilize, and select DICOM-compliant images; SoliPACS Report, offers a tool for generating customized reports; and Advanced Server Archive, a PACS storage system. It also provides UDE (Ubiquitous Diagnostic Environment) App, which converts standard iPad Pro into a standalone DICOM server, viewer, display, and Al all in one; MobiPACS Server to store, process, and retrieve image files for mobile devices; MobiPACS App, an in mobile medical image viewing app; MobiPACS Web Viewer for viewing images from Internet-enabled end devices; MobiPACS Share, a cloud-based platform; and MobiPACS Multi, supports doctors to connect various iPads/iPad Pros for image display. In addition, the company offers Vital-Sign On-the-Go, a patient monitoring solution; Rad@, for viewing medical-grade images and diagnose; Digital Pathology Scanner, transforms physical slides to whole side images; AgileRIS App, an offline reporting solution; EPS Pi, a viewer ready DICOM device; and UniGate_i (UGI) App. Further, it provides Telemed, which interlinks medical facilities; Electronic Medical Record, a digital version of the paper-based individual medical record for patients' medical history; Personal Health Record, offers electronic access to the individual's medical history; and eHealth solutions for retrieving and reviewing patient images, vital sign data, and ECG waveforms. The company was founded in 1988 and is headquartered in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
EBM Technologies Incorporated reported revenue of 253M TWD in FY2025 versus 195M TWD in FY2021, a compound +6.7%/yr. Reported net income was 7.8M TWD in FY2025.
8409 screens 73% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 126 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare EBM Technologies Incorporated with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is EBM Technologies Incorporated (8409) overvalued or undervalued?
What is the fair value of 8409?
What is the quality score of 8409?
What is the revenue of EBM Technologies Incorporated (8409)?
What is the net profit margin of 8409?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track EBM Technologies Incorporated and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.